| Cat. No. |
Product Name / Activity |
| 3066 |
L 006235 |
| Potent cathepsin K inhibitor |
| 5085 |
L 012 sodium salt |
| Chemiluminescent ROS and RNS indicator |
| 4013 |
L 760735 |
| High affinity NK1 antagonist |
| 6251 |
L Moses dihydrochloride |
| High affinity and selective PCAF bromodomain inhibitor |
| 2444 |
(1R,1'S,3'R/1R,1'R,3'S)-L-054,264 |
| Potent and selective sst2 agonist |
| 1382 |
L-152,804 |
| Potent, selective non-peptide NPY Y5 receptor antagonist |
| 2514 |
L-161,982 |
| Selective EP4 receptor antagonist |
| 1856 |
L-165,041 |
| Potent PPARδ agonist |
| 2311 |
L-168,049 |
| Potent, orally active human glucagon receptor antagonist |
| 2660 |
L-364,373 |
| KV7.1 channel activator, activates IKs |
| 2767 |
L-365,260 |
| Selective CCK2 antagonist |
| 2641 |
L-368,899 hydrochloride |
| Potent, non-peptide oxytocin receptor antagonist |
| 2410 |
L-371,257 |
| Potent and selective oxytocin receptor antagonist |
| 3086 |
L-651,582 |
| Non-selective Ca2+ channel blocker |
| 1327 |
L-655,708 |
| Benzodiazepine inverse agonist; selective for α5-containing GABAA receptors |
| 1949 |
L-670,596 |
| Potent, selective thromboxane A2/prostaglandin endoperoxide antagonist |
| 2627 |
L-685,458 |
| Potent and selective γ-secretase inhibitor |
| 0742 |
L-689,560 |
| Highly potent NMDA antagonist |
| 0682 |
L-690,488 |
| Cell permeable prodrug of the IMPase inhibitor L-690,330 (Cat. No. 0681) |
| 0681 |
L-690,330 |
| Inositol monophosphatase inhibitor |
| 2261 |
L-692,585 |
| Potent, non-peptide ghrelin receptor agonist |
| 0426 |
L-693,403 maleate |
| High affinity σ ligand |
| 0781 |
L-694,247 |
| 5-HT1D agonist |
| 0705 |
L-701,252 |
| NMDA antagonist; acts at glycine site |
| 0907 |
L-701,324 |
| NMDA antagonist; acts at glycine site |
| 2640 |
L-703,664 succinate |
| Selective 5-HT1D agonist |
| 0868 |
L-732,138 |
| Potent and selective NK1 antagonist |
| 1145 |
L-733,060 hydrochloride |
| Potent NK1 antagonist |
| 1004 |
L-741,742 hydrochloride |
| Highly selective D4 antagonist |
| 1003 |
L-741,626 |
| High affinity D2 antagonist |
| 1002 |
L-745,870 trihydrochloride |
| Highly selective D4 antagonist |
| 2760 |
L-748,337 |
| Selective β3 antagonist |
| 2197 |
L-755,507 |
| Very potent and selective β3 partial agonist |
| 3342 |
L-798,106 |
| Potent and highly selective EP3 antagonist |
| 1979 |
L-803,087 trifluoroacetate |
| Potent and selective sst4 agonist |
| 1980 |
L-817,818 |
| Potent and selective sst5 agonist |
| 3250 |
L-838,417 |
| GABAA partial agonist; displays subtype selectivity |
| 6954 |
L-Buthionine sulfoximine |
| Irreversible γ-glutamylcysteine synthetase (γ-GCS) inhibitor; induces ferroptosis |
| 6809 |
L-DON |
| Glutaminase inhibitor; also inhibits other glutamine-using enzymes and transporters |
| 3788 |
L-DOPA |
| Dopamine precursor |
| 5045 |
L002 |
| p300 inhibitor |
| 3561 |
L189 |
| DNA ligase I, III and IV inhibitor |
| 6146 |
LAP |
| Photocrosslinker for hydrogels |
| 5592 |
LCB 03-0110 dihydrochloride |
| Potent c-SRC kinase inhibitor; also inhibits DDR2, BTK and Syk |
| 6752 |
LDC 000067 |
| Potent and selective CDK9 inhibitor |
| 5631 |
LDN 193188 |
| Inhibitor of phosphatidylcholine transfer protein (PC-TP) |
| 6053 |
LDN 193189 dihydrochloride |
| Potent and selective ALK2 and ALK3 inhibitor; promotes neural induction of hPSCs |
| 4828 |
LDN 209929 dihydrochloride |
| Potent and selective haspin inhibitor |
| 5082 |
LDN 212320 |
| Increases EAAT2 expression; neuroprotective |
| 6151 |
LDN 212854 |
| Potent bone morphogenetic protein type I (ALK) inhibitor |
| 6152 |
LDN 214117 |
| Potent and selective ALK2 inhibitor |
| 4602 |
LDN 27219 |
| Transglutaminase 2 (TG2) inhibitor; reversible |
| 3998 |
LDN 57444 |
| Ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitor |
| 7020 |
LDV |
| α4β1 (VLA-4) ligand |
| 4577 |
LDV FITC |
| Fluorescent ligand for α4β1 (VLA-4) |
| 2021 |
LE 135 |
| Selective RARβ antagonist |
| 1674 |
LE 300 |
| Potent and selective D1 antagonist |
| 5826 |
LEI 101 hydrochloride |
| Potent and selective CB2 partial agonist; orally biovailable |
| 2985 |
LEP (116-130) (mouse) |
| Synthetic leptin peptide fragment |
| 4421 |
LF 11 |
| Antibiotic; neutralizes LPS |
| 1300 |
LFM-A13 |
| Potent, selective BTK inhibitor |
| 5920 |
LG 100268 |
| Potent and selective RXR agonist; also activates RXR/PPARγ heterodimers |
| 3831 |
LG 100754 |
| RXR:PPAR agonist |
| 3508 |
LG 101506 |
| Selective RXR modulator |
| 4896 |
LH 846 |
| Selective casein kinase 1δ inhibitor |
| 4745 |
LIMKi 3 |
| Potent LIM kinase inhibitor; antitumor |
| 6754 |
LJI308 |
| Potent pan-RSK inhibitor |
| 5213 |
LL 37 |
| Antimicrobial peptide derivative of human cathelicidin |
| 5365 |
LLY 507 |
| Potent SMYD2 inhibitor |
| 5794 |
LM 10 |
| Selective tryptophan 2,3-dioxygenase (TDO) inhibitor |
| 4607 |
LM 22A4 |
| Potent TrkB agonist |
| 5046 |
LM11A 31 dihydrochloride |
| Nonpeptide p75NTR ligand; neuroprotective |
| 6037 |
LM22B 10 |
| TrkB and TrkC agonist; brain penetrant |
| 4830 |
LMK 235 |
| Selective HDAC4/HDAC5 inhibitor |
| 6510 |
LNT 1 |
| Potent flap endonuclease 1 (FEN1) inhibitor; induces DNA damage response |
| 5606 |
LOC14 |
| High affinity protein disulfide isomerase (PDI) modulator |
| 2314 |
LOE 908 hydrochloride |
| Broad spectrum cation channel blocker; neuroprotective |
| 6691 |
LP 922056 |
| Notum inhibitor; activates Wnt signaling |
| 6229 |
LP 922761 |
| Potent AAK1 inhibitor; peripherally restricted |
| 5496 |
LP 99 |
| Selective BRD7 and BRD9 inhibitor |
| 4084 |
LPYFD-NH2 |
| Binds Aβ; protects from aggregation induced toxicity |
| 3394 |
LRGILS-NH2 |
| Control peptide for SLIGRL-NH2 (Cat. No. 1468) |
| 4273 |
LRRK2-IN-1 |
| Potent and selective LRRK2 inhibitor |
| 5275 |
LSN 2463359 |
| Potent and selective positive allosteric modulator of mGlu5 receptors |
| 5834 |
LTURM 34 |
| Potent DNA-PK inhibitor |
| 5835 |
LTURM 36 |
| PI 3-kinase δ inhibitor |
| 3562 |
LU AA33810 |
| Potent NPY Y5 receptor antagonist |
| 4603 |
LUF 5834 |
| Potent adenosine A2A and A2B receptor partial agonist |
| 4881 |
LUF 6283 |
| HCA2 (GPR109A) partial agonist |
| 7027 |
LY 2033298 |
| Selective positive allosteric modulator of M4 receptors; active in vivo; antipsychotic |
| 4141 |
LY 2087101 |
| Allosteric potentiator of α7, α4β2 and α4β4 nAChRs |
| 6964 |
LY 2119620 New |
| Positive allosteric modulator of M2 and M4 receptors |
| 1523 |
LY 215840 |
| 5-HT2/5-HT7 antagonist |
| 2452 |
LY 2183240 |
| Highly potent anandamide uptake inhibitor; also inhibits FAAH |
| 1018 |
LY 225910 |
| Potent CCK2 antagonist |
| 1286 |
LY 231617 |
| Antioxidant; neuroprotective in vitro and in vivo |
| 1521 |
LY 233053 |
| Competitive NMDA antagonist |
| 1019 |
LY 235959 |
| Competitive NMDA antagonist |
| 3397 |
LY 2365109 hydrochloride |
| Potent and selective GlyT1 inhibitor |
| 4969 |
LY 2389575 hydrochloride |
| Selective negative allosteric modulator of mGlu3 receptors |
| 2208 |
LY 255283 |
| Selective, competitive BLT2 receptor antagonist |
| 6454 |
LY 2603618 |
| Potent and selective Chk1 inhibitor |
| 4081 |
LY 266097 hydrochloride |
| Selective 5-HT2B antagonist |
| 3077 |
LY 272015 hydrochloride |
| High affinity 5-HT2B antagonist; orally active |
| 1524 |
LY 288513 |
| Selective CCK2 antagonist |
| 1130 |
LY 294002 hydrochloride |
| Prototypical PI 3-kinase inhibitor; also inhibits other kinases |
| 5984 |
LY 2955303 |
| High affinity and selective RARγ antagonist |
| 6854 |
LY 3009120 |
| Potent pan-Raf kinase inhibitor |
| 2418 |
LY 303511 |
| Negative control of LY 294002 (Cat. No. 1130) |
| 3078 |
LY 310762 hydrochloride |
| Selective 5-HT1D antagonist |
| 2387 |
LY 320135 |
| Selective CB1 inverse agonist |
| 4738 |
LY 333531 hydrochloride |
| Protein kinase C inhibitor; selective for β isozymes |
| 3079 |
LY 334370 hydrochloride |
| Selective 5-HT1F agonist |
| 1209 |
LY 341495 |
| Highly potent and selective group II mGlu antagonist |
| 4062 |
LY 341495 disodium salt |
| Potent and selective group II mGlu antagonist; disodium salt of LY 341495 (Cat. No. 1209) |
| 2451 |
LY 344864 hydrochloride |
| Potent and selective 5-HT1F agonist |
| 3246 |
LY 354740 |
| Potent and highly selective group II mGlu agonist |
| 2718 |
LY 364947 |
| Selective inhibitor of TGF-βRI |
| 1237 |
LY 367385 |
| Selective mGlu1a antagonist |
| 2453 |
LY 379268 |
| Highly selective group II mGlu agonist |
| 5064 |
LY 379268 disodium salt |
| Selective group II mGlu agonist; sodium salt of LY 379268 (Cat. No. 2453) |
| 3350 |
LY 393558 |
| Dual 5-HT1B and 5-HT1D antagonist; also 5-HT re-uptake inhibitor |
| 3272 |
(±)-LY 395756 |
| Mixed mGlu2 agonist/ mGlu3 antagonist |
| 5297 |
LY 404187 |
| Selective positive allosteric modulator of AMPA receptors |
| 6559 |
LY 450139 |
| γ-secretase pseudo-inhibitor |
| 2390 |
LY 456236 hydrochloride |
| Selective mGlu1 antagonist |
| 3283 |
LY 487379 hydrochloride |
| Selective positive allosteric modulator of mGlu2 receptors |
| 4060 |
LY 78335 |
| Phenylethanolamine-N-methyltransferase inhibitor |
| 2267 |
Lactacystin |
| Cell-permeable, potent and selective proteasome inhibitor |
| 6098 |
Lalistat 1 |
| Potent and selective LAL inhibitor |
| 6099 |
Lalistat 2 |
| Selective LAL inhibitor |
| 1611 |
Lamotrigine |
| Inhibits glutamate release. Anticonvulsant |
| 2289 |
Lamotrigine isethionate |
| Inhibits glutamate release. Water-soluble salt of lamotrigine (Cat. No. 1611) |
| 2582 |
Lansoprazole |
| H+,K+-ATPase inhibitor |
| 1293 |
β-Lapachone |
| DNA topoisomerase I inhibitor |
| 6811 |
Lapatinib |
| Potent and selective dual ErbB2 (HER-2) and EGFR inhibitor |
| 4757 |
Latanoprost |
| FP prostaglandin receptor agonist; also exhibits agonist activity at EP1 and EP3 receptors |
| 3973 |
Latrunculin A |
| Inhibitor of actin assembly and polymerization |
| 3974 |
Latrunculin B |
| Inhibitor of actin polymerization |
| 4007 |
Laulimalide |
| Microtubule stabilzing agent |
| 0548 |
(±)-Lauroylcarnitine chloride |
| Intermediate in lipid metabolism |
| 4422 |
Lauryl-LF 11 |
| Analog of LF 11 (Cat. No. 4421); antibiotic |
| 1331 |
Lavendustin A |
| EGFR, p60c-src inhibitor |
| 2460 |
Lazabemide hydrochloride |
| Selective MAO-B inhibitor |
| 2139 |
Leelamine hydrochloride |
| CB1 agonist |
| 2228 |
Leflunomide |
| Inhibitor of DHODH |
| 5571 |
Lei-Dab 7 |
| High affinity, selective KCa2.2 blocker |
| 6305 |
Lenalidomide |
| Cereblon binder; induces ubiquitination and degradation of CK1α by E3 ubiquitin ligase |
| 1987 |
Leptomycin B |
| Inhibits nuclear export of proteins; antitumor |
| 2959 |
Lercanidipine hydrochloride |
| CaV1.x blocker |
| 3395 |
Lestaurtinib |
| JAK2, FLT3 and TrkA inhibitor; also inhibits AurA and AurB |
| 4382 |
Letrozole |
| Potent, reversible non-steroidal aromatase inhibitor |
| 4921 |
Leukadherin 1 |
| Allosteric activator of CD11b/CD18 |
| 2307 |
Leukotriene B4 |
| BLT1/BLT2 receptor agonist and potent chemotactic factor |
| 1167 |
Leupeptin hemisulfate |
| Inhibits trypsin-like/cysteine proteases |
| 2873 |
Leuprolide |
| GnRH receptor agonist |
| 1378 |
Levcromakalim |
| Kir6 (KATP) channel opener; active enantiomer of cromakalim (Cat. No. 1377) |
| 2839 |
Levetiracetam |
| Antiepileptic; binds SV2A |
| 4833 |
Levonorgestrel |
| Synthetic progesterone analog |
| 2705 |
Liarozole dihydrochloride |
| Blocks retinoic acid metabolism |
| 3865 |
Licarbazepine |
| Active metabolite of oxcarbazepine (Cat. No. 3864) |
| 3057 |
Lidocaine |
| Na+ channel blocker |
| 6068 |
Lin28 1632 |
| RNA binding protein Lin28 inhibitor; promotes mESC differentiation; also bromodomain inhibitor |
| 3765 |
Linezolid |
| Antibiotic; inhibits protein synthesis in gram-positive bacteria |
| 1461 |
Linomide |
| Immunomodulator with antiangiogenic properties |
| 1999 |
Linopirdine dihydrochloride |
| KV7 (KCNQ) channel blocker |
| 7045 |
(±)-α-Lipoamide |
| Phase-separated condensate modifier; orally bioavailable |
| 7044 |
(±)-α-Lipoic acid |
| Liquid-liquid phase separated condensate modifier; reduces stress granule formation |
| 6113 |
Liproxstatin-1 hydrochloride |
| Potent ferroptosis inhibitor |
| 6517 |
Liraglutide |
| Highly potent, long-acting GLP-1 receptor agonist |
| 4052 |
Lisuride maleate |
| Dopamine agonist; antiparkinson's agent |
| 4740 |
Lithium carbonate |
| Mood stabilizer; inhibits GSK-3 in vivo |
| 1916 |
Litorin |
| Amphibian bombesin-like peptide |
| 1077 |
(-)-Lobeline hydrochloride |
| Nicotinic partial agonist |
| 2690 |
Locustatachykinin I |
| Insect tachykinin-related peptide (TRP) |
| 2545 |
Lofepramine |
| 5-HT and NA reuptake inhibitor (SNRI) |
| 4359 |
Lomeguatrib |
| MGMT inhibitor |
| 6265 |
Lonafarnib |
| Potent farnesyltransferase inhibitor |
| 1646 |
Lonidamine |
| Mitochondrial hexokinase inhibitor |
| 0840 |
Loperamide hydrochloride |
| Peripherally acting μ agonist; Ca2+ channel blocker |
| 1944 |
Loratidine |
| Peripheral H1 antagonist; antiallergic agent |
| 3087 |
Lorazepam |
| Ligand at benzodiazepine site |
| 1295 |
Loreclezole hydrochloride |
| Subtype-selective GABAA modulator |
| 3798 |
Losartan potassium |
| Selective, non-peptide AT1 antagonist |
| 1530 |
Lovastatin |
| Potent HMG-CoA reductase inhibitor |
| 3036 |
Loxiglumide |
| CCK1 antagonist; active in vivo |
| 5427 |
D-Luciferin sodium salt |
| Firefly luciferase substrate; cell permeable. |
| 2874 |
Luteolin |
| Anti-inflammatory, antioxidant and free radical scavenger |
| 0877 |
Luzindole |
| Competitive melatonin MT1/MT2 antagonist |
| 2265 |
Lyn peptide inhibitor |
| Inhibits Lyn-dependent activities of IL-5 receptor; cell-permeable |
| 5103 |
Lys-CoA |
| Selective p300 inhibitor |
| 3611 |
Lys-γ3-MSH |
| Pro-opiomelanocortin (POMC) derived peptide |